Abstract: Various embodiments of the present disclosure provide methods, apparatuses, systems, computing devices, computing entities, and/or the like for determining optimized solutions to input problems in a containerized, cloud-based (e.g., serverless) manner. In one embodiment, an example method is provided. The method comprises: receiving a problem type of an input problem originating from a client computing entity; mapping the problem type to one or more selected solver types; generating one or more container instances of one or more compute containers, each compute container corresponding to a selected solver type; generating a problem output using the one or more container instances; and providing the problem output comprising a solution to the input problem to the client computing entity.

Abstract: Various embodiments of the present disclosure provide methods, apparatuses, systems, computing devices, computing entities, and/or the like for determining optimized solutions to input problems in a containerized, cloud-based (e.g., serverless) manner using multiple solver types. In one embodiment, an example method involves receiving a problem type of an input problem originating from a client computing entity, mapping the problem type to one or more selected solver types, generating one or more container instances of one or more compute containers with each compute container corresponding to a selected solver type, generating a problem output using the one or more container instances, and providing the problem output to the client computing entity, where the problem output includes an optimized solution to the input problem that can be used to perform one or more prediction-based actions.

Abstract: The invention relates to immunogenic polysaccharide-protein conjugates comprising a capsular polysaccharide (CP) from Streptococcus agalactiae, commonly referred to as group B streptococcus (GBS), and a carrier protein, wherein the CP is selected from the group consisting of serotypes Ia, Ib, II, III, IV, V, VI, VII, VIII, and IX, and wherein the CP has a sialic acid level of greater than about 60%. The invention also relates to methods of making the conjugates and immunogenic compositions comprising the conjugates. The invention further relates to methods for inducing an immune response in subjects against GBS and/or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy.

Abstract: The present disclosure relates to RSV F protein mutants, nucleic acids or vectors encoding a RSV F protein mutant, compositions comprising a RSV F protein mutant or nucleic acid, and uses of the RSV F protein mutants, nucleic acids or vectors, and compositions.

Abstract: Various embodiments of the present disclosure provide methods, apparatuses, systems, computing devices, computing entities, and/or the like for determining optimized solutions to input problems in a containerized, cloud-based (e.g., serverless) manner. In one embodiment, an example method is provided. The method comprises: receiving a problem type of an input problem originating from a client computing entity; mapping the problem type to one or more selected solver types; generating one or more container instances of one or more compute containers, each compute container corresponding to a selected solver type; generating a problem output using the one or more container instances; and providing the problem output comprising a solution to the input problem to the client computing entity.

Abstract: Various embodiments of the present disclosure provide methods, apparatuses, systems, computing devices, computing entities, and/or the like for determining optimized solutions to input problems in a containerized, cloud-based (e.g., serverless) manner using multiple solver types. In one embodiment, an example method involves receiving a problem type of an input problem originating from a client computing entity, mapping the problem type to one or more selected solver types, generating one or more container instances of one or more compute containers with each compute container corresponding to a selected solver type, generating a problem output using the one or more container instances, and providing the problem output to the client computing entity, where the problem output includes an optimized solution to the input problem that can be used to perform one or more prediction-based actions.

Abstract: Various embodiments of the present disclosure provide methods, apparatuses, systems, computing devices, computing entities, and/or the like for determining optimized solutions to input problems in a containerized, cloud-based (e.g., serverless) manner. In one embodiment, an example method is provided. The method comprises: receiving a problem type of an input problem originating from a client computing entity; mapping the problem type to one or more selected solver types; generating one or more container instances of one or more compute containers, each compute container corresponding to a selected solver type; generating a problem output using the one or more container instances; and providing the problem output comprising a solution to the input problem to the client computing entity.

Abstract: In one aspect, the invention relates to a polypeptide derived from E. coli and a fragment thereof, including compositions and methods thereof. Also disclosed herein are compositions that include a polypeptide derived from E. coli and a fragment thereof; and modified O-polysaccharide molecules derived from E. coli lipopolysaccharides and conjugates thereof. In a further aspect, disclosed herein are mammalian host cells that include sequence(s) encoding a polypeptide derived from E. coli or fragments thereof.

Abstract: In one aspect, the invention relates to an immunogenic composition comprising modified O-polysaccharide molecules derived from E. coli lipopolysaccharides and conjugates thereof. Multivalent vaccines may be prepared by combining two or more monovalent immunogenic compositions for different E. coli serotypes. In one embodiment, the modified O-polysaccharide molecules are produced by a recombinant bacterium that includes a wzz gene.

Abstract: In one aspect, the invention relates to an immunogenic composition comprising modified O-polysaccharide molecules derived from E. coli lipopolysaccharides and conjugates thereof. Multivalent vaccines may be prepared by combining two or more monovalent immunogenic compositions for different E. coli serotypes. In one embodiment, the modified O-polysaccharide molecules are produced by a recombinant bacterium that includes a wzz gene.

Abstract: The present disclosure relates to RSV F protein mutants, nucleic acids or vectors encoding a RSV F protein mutant, compositions comprising a RSV F protein mutant or nucleic acid, and uses of the RSV F protein mutants, nucleic acids or vectors, and compositions.

Abstract: The present disclosure relates to RSV F protein mutants, nucleic acids or vectors encoding a RSV F protein mutant, compositions comprising a RSV F protein mutant or nucleic acid, and uses of the RSV F protein mutants, nucleic acids or vectors, and compositions.

Abstract: In one aspect, the invention relates to an immunogenic composition comprising modified O-polysaccharide molecules derived from E. coli lipopolysaccharides and conjugates thereof. Multivalent vaccines may be prepared by combining two or more monovalent immunogenic compositions for different E. coli serotypes. In one embodiment, the modified O-polysaccharide molecules are produced by a recombinant bacterium that includes a wzz gene.

Abstract: The present disclosure relates to RSV F protein mutants, nucleic acids or vectors encoding a RSV F protein mutant, compositions comprising a RSV F protein mutant or nucleic acid, and uses of the RSV F protein mutants, nucleic acids or vectors, and compositions.

Abstract: The present disclosure relates to RSV F protein mutants, nucleic acids or vectors encoding a RSV F protein mutant, compositions comprising a RSV F protein mutant or nucleic acid, and uses of the RSV F protein mutants, nucleic acids or vectors, and compositions.

Abstract: The subject disclosure describes solutions for graphically displaying hierarchical relationships between a network underlay and a network overlay. In some aspects, a method of the technology includes steps for aggregating associations between each of a plurality of physical network devices and one or more virtual network entities, displaying two or more pivot options that graphically represent the physical network devices and/or the virtual network entities, and receiving a pivot selection indicating at least one physical network device or virtual network entity for which hierarchy information is requested by a user. In some aspects, the method can further include steps for graphically displaying one or more layers of a network hierarchy based on the pivot selection. Systems and machine-readable media are also provided.

Abstract: The present disclosure relates to RSV F protein mutants, nucleic acids or vectors encoding a RSV F protein mutant, compositions comprising a RSV F protein mutant or nucleic acid, and uses of the RSV F protein mutants, nucleic acids or vectors, and compositions.

Abstract: The present disclosure relates to RSV F protein mutants, nucleic acids or vectors encoding a RSV F protein mutant, compositions comprising a RSV F protein mutant or nucleic acid, and uses of the RSV F protein mutants, nucleic acids or vectors, and compositions.

Abstract: In some implementations, a method includes obtaining a first visual representation of a first network topology of a network and a second visual representation of a second network topology. The first network topology includes a first set of network devices and a first set of connections between the first set of network devices. The second network topology includes a second set of network devices and a second set of connections between the second set of network devices. The method also includes alternating between presenting the first visual representation and presenting the second visual representation based on user input.

Abstract: The invention relates to novel saccharides and uses thereof. In one aspect, the invention relates to a saccharide having a legionaminic acid moiety, a N-acetylgalactosamine moiety, a galactose moiety, and a glucose moiety. In another aspect, the invention relates to a saccharide having an altruronic acid moiety, a fucose moiety, and a glucose moiety. In yet another aspect, the invention relates to a saccharide having a repeating unit of a glycerol phosphate moiety and a glucose moiety, wherein the saccharide is from Enterococcus faecium. In a further aspect, the invention relates to a saccharide having a repeating unit of -6-?-D-Fruf-2, wherein Fru is a fructose moiety, wherein the saccharide is from Enterococcus faecium. In another aspect, the invention relates to an isolated antibody or fragment thereof that specifically binds to a saccharide described herein and uses thereof.